Iannone Robert sold $19.2M of JAZZ

Piper Sandler raised its price target for Jazz Pharmaceuticals to $330 from $310, maintaining an Overweight rating. This implies a 32.9% upside from the Nov 11 close of $248.24. Recent analyst targets for the company range from $275 to $319.

Bernstein lowered its price target for Jazz Pharmaceuticals (JAZZ) to $220 from $229, citing competition from Amgen's Imdelltra for Zepzelca in small cell lung cancer. Jazz's stock is up 79% in the past year. Jazz reported Q3 revenue of $1.24B, up 10% YoY, but a loss per share of $3.88 due to an IPR&D charge. Baird reiterated an Outperform rating with a $280 target.

Jazz Pharmaceuticals (JAZZ) reported Q3 2026 earnings, raising guidance driven by strong Xywav performance and removing downside scenarios in other segments. Challenges include competitive headwinds for Zepzelca and measured Modeyso revenue growth. Ziihera showed strong community adoption, with 80% of new orders from community accounts. Xywav saw 12% growth and 425 net patient adds, with no expected impact from generics.

Jazz Pharmaceuticals reported Q3 2026 revenues of $1.2B, up 10% YoY, and raised full-year guidance. The company expanded its epilepsy portfolio by acquiring Actio Biosciences and launched a new treatment for HER2+ gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals (JAZZ) shares rose 8.4% after reporting Q3 2026 revenue of $1.24B, up 10.4% YoY, and raising full-year guidance to $4.81B. EPS of -$3.88 missed estimates. The company's stock has gained 33.6% YTD but remains 11.6% below its 52-week high.

Jazz Pharmaceuticals (JAZZ) shares rose ~8% after the company raised its 2026 revenue forecast to $4.775B-$4.85B, up from $4.6B-$4.75B. The company also reported Q3 results that exceeded revenue expectations, with consensus at $4.8B.